News
Minimum wage increases improve women’s health, study finds
A new study found that increasing minimum wage may improve women’s health.
Researchers from the University of Maine also found that increasing the minimum wage may harms low-educated and low-income men’s health in the same demographic category as women.
The study analysed 2011-2019 data from the Behavioural Risk Factor Surveillance Survey, a large annual telephone survey in which participants rate their general health on a five-point scale and report the number of days in the past month when they experienced poor physical or mental health.
Researchers compared those measures to changes in the minimum wage rates finding that a 10 per cent increase improved women’s general health and reduced their physical and mental health burdens.
Lead author of the study Liam Sigaud said: “We’re excited to contribute to this important and fast-growing area of research. With so much interest in minimum wage policy at all levels of government, we hope our work can inform decision-making in a positive way.
“By using more recent data that better captures the current state of economy, our study is a strong complement to the existing literature on this topic.”
On the other hand, the results of the study for men were more complicated. While higher minimum wages increased men’s physical and mental health burdens, the effect on men’s general health was ambiguous.
“Although our study hints at possible pathways, there’s still a lot we don’t know about why higher minimum wages affect the health of men and women differently,” said Sigaud, “It’s probably a complicated mix of factors related to family roles, occupational choices and behaviours that differ across genders.
“We hope future work can elucidate these mechanisms. As the data and quantitative tools to explore these questions constantly improve, we’re going to have better and better insights.”
The minimum wage rates in the UK increased on the 1st of April 2022, going from £8.91 to £9.50 which represents a 6.6 per cent increase.
According to census 2021, the gender pay gap in the UK has been declining slowly over time, falling by approximately a quarter among both full-time employees and all employees over the last decade.
Insight
Topical HRT protects bone density in women with period loss – study
Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.
The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.
Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.
Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.
The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.
Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.
“Our study provides much needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.
“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”
When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.
The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.
They found no significant benefit for oral contraceptive pills or oral hormone therapy.
A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.
Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.
“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.
“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”
Insight
AI cuts interval breast cancers in Swedish trial
Wellness
Fear of ageing may age women faster, study suggests
-
Insight4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Events4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026






